Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 0.14
NAVB's Cash to Debt is ranked lower than
53% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. NAVB: 0.14 )
NAVB' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: 0.14

Equity to Asset -3.28
NAVB's Equity to Asset is ranked lower than
53% of the 1112 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. NAVB: -3.28 )
NAVB' s 10-Year Equity to Asset Range
Min: -3.6   Max: 0.94
Current: -3.28

-3.6
0.94
F-Score: 4
Z-Score: -52.12
M-Score: -1.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -352.12
NAVB's Operating margin (%) is ranked higher than
62% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -82.48 vs. NAVB: -352.12 )
NAVB' s 10-Year Operating margin (%) Range
Min: -35429.11   Max: 13.25
Current: -352.12

-35429.11
13.25
Net-margin (%) -409.87
NAVB's Net-margin (%) is ranked higher than
61% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. NAVB: -409.87 )
NAVB' s 10-Year Net-margin (%) Range
Min: -36907.59   Max: 938.63
Current: -409.87

-36907.59
938.63
ROA (%) -161.71
NAVB's ROA (%) is ranked higher than
50% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. NAVB: -161.71 )
NAVB' s 10-Year ROA (%) Range
Min: -502.64   Max: 26.69
Current: -161.71

-502.64
26.69
ROC (Joel Greenblatt) (%) -1025.81
NAVB's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. NAVB: -1025.81 )
NAVB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4904.17   Max: 145.59
Current: -1025.81

-4904.17
145.59
Revenue Growth (3Y)(%) 58.70
NAVB's Revenue Growth (3Y)(%) is ranked higher than
97% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. NAVB: 58.70 )
NAVB' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100   Max: 89.8
Current: 58.7

-100
89.8
EBITDA Growth (3Y)(%) -8.00
NAVB's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. NAVB: -8.00 )
NAVB' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 141
Current: -8

0
141
EPS Growth (3Y)(%) 8.10
NAVB's EPS Growth (3Y)(%) is ranked higher than
83% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NAVB: 8.10 )
NAVB' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 112.7
Current: 8.1

0
112.7
» NAVB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014
Q3 2014
Q4 2014
Q1 2015
» Details

Insider Trades

Latest Guru Trades with NAVB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 25.75
NAVB's P/S is ranked higher than
58% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 40.50 vs. NAVB: 25.75 )
NAVB' s 10-Year P/S Range
Min: 1.9   Max: 203
Current: 25.75

1.9
203
EV-to-EBIT -8.50
NAVB's EV-to-EBIT is ranked lower than
53% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NAVB: -8.50 )
NAVB' s 10-Year EV-to-EBIT Range
Min: -92.9   Max: -3.9
Current: -8.5

-92.9
-3.9
Current Ratio 0.62
NAVB's Current Ratio is ranked lower than
51% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. NAVB: 0.62 )
NAVB' s 10-Year Current Ratio Range
Min: 0.62   Max: 17.92
Current: 0.62

0.62
17.92
Quick Ratio 0.58
NAVB's Quick Ratio is ranked higher than
50% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. NAVB: 0.58 )
NAVB' s 10-Year Quick Ratio Range
Min: 0.48   Max: 17.8
Current: 0.58

0.48
17.8
Days Inventory 263.31
NAVB's Days Inventory is ranked higher than
80% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NAVB: 263.31 )
NAVB' s 10-Year Days Inventory Range
Min: 70.99   Max: 1386.56
Current: 263.31

70.99
1386.56
Days Sales Outstanding 57.92
NAVB's Days Sales Outstanding is ranked higher than
85% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. NAVB: 57.92 )
NAVB' s 10-Year Days Sales Outstanding Range
Min: 9.77   Max: 371.45
Current: 57.92

9.77
371.45

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 3.00
NAVB's Price/Median PS Value is ranked higher than
62% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. NAVB: 3.00 )
NAVB' s 10-Year Price/Median PS Value Range
Min: 0.06   Max: 33.33
Current: 3

0.06
33.33
Earnings Yield (Greenblatt) -11.80
NAVB's Earnings Yield (Greenblatt) is ranked higher than
55% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. NAVB: -11.80 )
NAVB' s 10-Year Earnings Yield (Greenblatt) Range
Min: -14.1   Max: 0
Current: -11.8

-14.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:MDT, SYK, SMA, ZMH, STJ » details
Navidea Biopharmaceuticals Inc was incorporated in Ohio in 1983 and reincorporated in Delaware in 1988. It is a biopharmaceutical company engaged in the development and commercialization of precision diagnostics and radiopharmaceutical agent. Its products include Lymphoseek Injection is a novel, receptor-targeted, small-molecule radiopharmaceutical used in lymphatic mapping procedures that are performed to help evaluate patients with breast cancer and melanoma. Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on macrophages. This flexible and versatile platform acts as an engine for the design of purpose-built molecules offering the potential to be utilized across a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography, intra-operative and/or optical-fluorescence detection in a variety of disease states. NAV4694 is a Fluorine-18 radiolabeled PET imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease and mild cognitive impairment. NAV5001 is an Iodine-123 radiolabeled SPECT imaging agent being developed as an aid in the diagnosis of Parkinson's disease and other movement disorders, with potential use as a diagnostic aid in dementia. NAV1800 is a radiolabeled monoclonal antibody being developed as a diagnostic aid for use during surgery to help surgeons locate occult or metastatic cancer, with a focus on colorectal cancer. It faces competition from medical product and biotechnology companies, as well as from universities and other non-profit research organizations in the field of cancer diagnostics and treatment. As a developer, manufacturer and marketer of medical products, the Company is subject to regulation by, among other governmental entities, FDA and the corresponding state, local and foreign regulatory bodies in jurisdictions in which its products are sold.
» More Articles for NAVB

Headlines

Articles On GuruFocus.com
Navidea Biopharmaceuticals Reports 4 Insider Trades Mar 18 2013 
comment on NAVB Mar 15 2013 

More From Other Websites
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement,... May 21 2015
NAVIDEA BIOPHARMACEUTICALS, INC. Financials May 20 2015
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... May 15 2015
10-Q for Navidea Biopharmaceuticals, Inc. May 13 2015
Navidea Biopharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today May 12 2015
Navidea Reports First Quarter 2015 Financial Results; Reiterates 2015 Lymphoseek® Revenue Guidance May 12 2015
Navidea reports 1Q loss May 12 2015
Navidea reports 1Q loss May 12 2015
Navidea Reports First Quarter 2015 Financial Results; Reiterates 2015 Lymphoseek® Revenue Guidance May 12 2015
Q1 2015 Navidea Biopharmaceuticals Inc Earnings Release - Before Market Open May 12 2015
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 11 2015
Navidea Secures $60 Million Loan with CRG; Funding to Support Lymphoseek® Commercialization and... May 11 2015
Navidea Secures $60 Million Loan with CRG; Funding to Support Lymphoseek® Commercialization and... May 11 2015
10-K for Navidea Biopharmaceuticals, Inc. May 04 2015
Navidea Biopharmaceuticals to Announce First Quarter 2015 Financial Results on May 12, 2015 Apr 30 2015
Navidea Biopharmaceuticals to Announce First Quarter 2015 Financial Results on May 12, 2015 Apr 30 2015
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Apr 27 2015
Navidea Divests NAV5001, a Non-Core, Development-Stage Imaging Agent for Parkinson's Disease Apr 27 2015
Navidea Divests NAV5001, a Non-Core, Development-Stage Imaging Agent for Parkinson's Disease Apr 27 2015
Navidea Data for Manocept™ CD206 Targeting Platform Demonstrate Potential to Impact... Apr 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK